INTRODUCTION AND OBJECTIVES: High-Intensity Focused Ultrasound (HIFU) is an emerging treatment for localized prostate cancer patients. HIFU is a noninvasive technique that induces coagulative necrosis in tumors without surgical exposure or insertion of instruments into the lesion. We evaluated the association between clinical outcomes and biochemical failure (BCR).
METHODS: From June 2006 to November 2014, 259 consecutive patients with T1-2 prostate cancer were treated with Sonablate? (SB) devices. After HIFU, prostate-specific antigen (PSA) was measured every 3 months. BCR was defined according to the Stuttgart definition (a rise of 1.2 ng/ml or more above the nadir PSA). Serum PSA level was increased rapidly after HIFU. Then, PSA flare was determined an increase of 3.0 ng/ml with a spontaneous return to the pre-flare level or lower. Predictors for BCR was identified using the Cox-proportional hazard method.
RESULTS: A total of 259 patients with a median age of 67.6 years were followed for median duration of 59 months. Mean pretreatment PSA was 9.6 ng/ml. Mean pretreatment prostate volume was 28. (May/2015 -Nov/2015 . Patients had a single lesion injected transperineally using MRI-ultrasound image-fusion software (SmartTargetâ), under general anaesthetic with up to 5mL of a standard dosing solution (20ug/mL) of PRX302. Follow-up occurred at 2 days and at 2, 6, 12, 24 and 26 weeks. A mpMRI-targeted transperineal biopsy of the treated area was performed at 24 weeks. All men who enrolled completed the study.
RESULTS: Median age and PSA were 66.50 years (IQR 13.00) and 6.25ng/ml (IQR 2.45). 4 patients (22%) had high volume Gleason 6 and 14 (78%) had Gleason 7 cancer with median lesion size 0.3mL (IQR 0.2-0.5). The administration of PRX302 was well tolerated with no serious adverse events and no new safety signals. At 24 weeks following treatment, 2 had complete tumour ablation (no histological evidence of cancer). These 2 showed reductions in PSA of 3.0 to 2.2ng/ mL (26.7%) and 5.7 to 4.8ng/mL (15.8%), respectively. Seven had partial response defined as reductions in MCCL or Gleason grade. 9 had no histological response, with some experiencing increases in MCCL or grade.
CONCLUSIONS: Our proof-of-concept study shows that a single intraprostatic administration of PRX302 has a biological effect on prostate tumor cells when focally injected with low side-effect profile.
Optimizing the dosing and delivery of PRX302 based on tumour size may increase response rates and will be tested in a multicenter phase 2 study.
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MP70-16 SAFETY AND FEASIBILITY OF REAL-TIME MRI-GUIDED FOCUSED ULTRASOUND FOR FOCAL THERAPY OF LOCALIZED PROSTATE CANCER USING THE EXABLATE 2100 DEVICE: PHASE 1 STUDY
Nathan Perlis*, Eugen Hlasny, Walter Kucharczyk, Masoom Haider, Antonio Finelli, Alexandre Zlotta, Girish Kulkarni, John Trachtenberg, Sangeet Ghai, Toronto, Canada INTRODUCTION AND OBJECTIVES: Organ preserving therapy is emerging as an option for localized prostate cancer to minimize the morbidity associated with whole-gland therapy. We examine the short-term oncologic and functional data of the initial phase 1 trial of patients treated with focal transrectal MRI-guided focused ultrasound (MRgFUS) in North America.
METHODS: This phase 1 prospective study was approved by institutional review board. Eight patients with organ-confined PC visible on multiparametric MRI (mpMRI) and confirmed by the MRI-fusion biopsy (Artemis, Eigen) were enrolled. Patients were eligible with PSA 10ng/mL and Gleason score (GS) 7(4+3). Tumors larger than 1.5 cm in any dimension, too peripheral for a 5mm ablation margin or with concern for extraprostatic extension were excluded. Under MRI-guidance and real-time MR thermography, focal lesions were ablated using high frequency ultrasound energy delivered via an endorectal transducer with 990 elements (ExAblate 2100, InSightec). Incidence and severity of treatment-related adverse events were recorded at 6 months.
RESULTS: Eight patients with 10 peripheral zone lesions were treated. Prostate volume ranged from 25 to 50 cc with mean target volume of 2.7cc (range 0.4 -5.7cc). Mean procedure time was 248 minutes. Based on pre-treatment biopsy, six lesions were GS6(3+3), two were GS7(3+4) and two others were GS7(4+3). Treatments were all completed as planned without major technical delays or surgical complications. Mean post treatment non-perfused volume was 4.3cc (range 2.2 -7.6cc). Quality of life parameters were similar between baseline and 6-months in 6 of 8 patients. One patient with bilateral ablation had significantly worse storage symptoms while a second patient developed self-limiting acute prostatitis with erectile dysfunction. Mean PSA decreased from 5.06 to 3.4 ng/ml at 6 months. All patients were MRI negative in their treated regions. On biopsy, five patients were disease-free in treated regions (7 of 10 lesions). In one patient with a presumed GS7(4+3) tumor, a 2mm MRI-invisible focus of GS8(4+4) PC was seen in 1 of 5 cores from the ablation site. He underwent prostatectomy with negative surgical margins.
CONCLUSIONS: MRgFUS is a feasible and safe method of ablating localized PC. Further work is required to improve patient selection and address causes of failed ablation. Our study is limited by small sample size and brief follow-up. More meaningful oncologic and functional outcomes for MRgFUS can be assessed with larger trials with longer follow-up. 
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